Prostate cancer UK's Risk Checker: help or hindrance to PSA testing policy?

informed choice prostate cancer psa

Journal

BJGP open
ISSN: 2398-3795
Titre abrégé: BJGP Open
Pays: England
ID NLM: 101713531

Informations de publication

Date de publication:
29 Feb 2024
Historique:
received: 08 02 2024
accepted: 23 02 2024
revised: 23 02 2024
medline: 1 3 2024
pubmed: 1 3 2024
entrez: 29 2 2024
Statut: aheadofprint

Résumé

The UK has an informed choice prostate cancer testing policy, where the PSA blood test is available for free to any man aged 50 or over who request it and has been informed of the harms and benefits. This leads to differences in PSA testing rates which can exacerbate health inequalities. To assess whether Prostate Cancer UK's Risk Checker helps men at risk of prostate cancer make an informed choice about the PSA test. Mixed methods study, UK. 1,181 men at risk, their partners, and clinical experts participated in surveys, focus groups, and 1:1 interviews. Data on risk checker completions by sociodemographic factors were analysed over time. Data from GP practices that sent the Risk Checker to their patients were collected and analysed for service monitoring purposes. There was a strong assumption that testing must be good, and therefore a need to emphasise the pros and cons of the test and that having it was the patient's decision. Men believed their GP would invite them for PSA testing. 80% of men who completed the risk checker had at least one prostate cancer risk factor. Average time they interacted with the information in the tool was 9 minutes 28 seconds. 75.7% felt the tool had equipped them to make an informed choice. Online decision-making tools like the Risk Checker can help reach men at high risk of prostate cancer and support them in making an informed choice about the PSA test.

Sections du résumé

BACKGROUND BACKGROUND
The UK has an informed choice prostate cancer testing policy, where the PSA blood test is available for free to any man aged 50 or over who request it and has been informed of the harms and benefits. This leads to differences in PSA testing rates which can exacerbate health inequalities.
AIM OBJECTIVE
To assess whether Prostate Cancer UK's Risk Checker helps men at risk of prostate cancer make an informed choice about the PSA test.
DESIGN & SETTING METHODS
Mixed methods study, UK.
METHOD METHODS
1,181 men at risk, their partners, and clinical experts participated in surveys, focus groups, and 1:1 interviews. Data on risk checker completions by sociodemographic factors were analysed over time. Data from GP practices that sent the Risk Checker to their patients were collected and analysed for service monitoring purposes.
RESULTS RESULTS
There was a strong assumption that testing must be good, and therefore a need to emphasise the pros and cons of the test and that having it was the patient's decision. Men believed their GP would invite them for PSA testing. 80% of men who completed the risk checker had at least one prostate cancer risk factor. Average time they interacted with the information in the tool was 9 minutes 28 seconds. 75.7% felt the tool had equipped them to make an informed choice.
CONCLUSION CONCLUSIONS
Online decision-making tools like the Risk Checker can help reach men at high risk of prostate cancer and support them in making an informed choice about the PSA test.

Identifiants

pubmed: 38423621
pii: BJGPO.2024.0040
doi: 10.3399/BJGPO.2024.0040
pii:
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

Copyright © 2024, The Authors.

Auteurs

Natalia Norori (N)

Prostate Cancer UK, London, United Kingdom Natalia.norori@prostatecanceruk.org.

Chiara de Biase (C)

Prostate Cancer UK, London, United Kingdom.

Yui Hang Wong (YH)

Prostate Cancer UK, London, United Kingdom.

Sadie Robson Crabtree (SR)

Prostate Cancer UK, London, United Kingdom.

Matt Cox (M)

Prostate Cancer UK, London, United Kingdom.

Esther Appleby (E)

Southeast London Cancer Alliance, London, United Kingdom.
Lewisham Borough, London, United Kingdom.

Andrew Seggie (A)

Prostate Cancer UK, London, United Kingdom.

Rachel Brown (R)

Bristol Inner City PCN and Montpelier Health Centre, Bristol, United Kingdom.

Amy Rylance (A)

Prostate Cancer UK, London, United Kingdom.

Classifications MeSH